FcRH1 Inhibitors
FcRH1 inhibitors are a class of chemical compounds that specifically target the Fc receptor homolog 1 (FcRH1), a protein predominantly expressed on the surface of B lymphocytes. These inhibitors are designed to modulate the function of FcRH1 by binding to its extracellular domains, thereby influencing its role in immune cell signaling. The chemical structures of FcRH1 inhibitors can vary widely, encompassing small organic molecules, peptides, or engineered proteins. These compounds are often developed through processes like high-throughput screening and structure-based design to ensure high specificity and affinity for FcRH1. Molecular interactions such as hydrogen bonding, hydrophobic contacts, and electrostatic forces are critical for the binding efficacy of these inhibitors.
The mechanism of action of FcRH1 inhibitors involves interfering with the normal signaling pathways mediated by FcRH1. By binding to the receptor, these inhibitors can prevent the interaction of FcRH1 with its natural ligands, leading to alterations in downstream signaling events within B cells. This can affect various cellular processes, including activation, proliferation, and differentiation. Structural studies using techniques like X-ray crystallography and nuclear magnetic resonance spectroscopy have provided insights into the binding sites and conformational changes associated with inhibitor interaction. Understanding these molecular details is crucial for optimizing the design of FcRH1 inhibitors and for elucidating the role of FcRH1 in immune regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could hypothetically decrease FcRH1 expression by causing demethylation of gene promoter regions, thus potentially altering the transcriptional activity of the FCRL1 gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A may lead to a more acetylated and less transcriptionally active chromatin state at the FCRL1 locus, potentially resulting in reduced FcRH1 synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin might downregulate FcRH1 expression by inhibiting the mTOR signaling pathway, which plays a crucial role in B cell development and differentiation, where FcRH1 is involved. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A could decrease FcRH1 expression by inhibiting calcineurin, leading to reduced activation of NFAT, a transcription factor that may be necessary for FCRL1 gene expression in B cells. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate may lead to reduced FcRH1 expression by interfering with the synthesis of nucleotides, thus hindering the proliferation of B-cells and the consequent demand for FcRH1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib might downregulate FcRH1 by preventing the degradation of IκB, an inhibitor of NF-κB; a transcription factor that could be essential for FCRL1 gene expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 could lead to decreased FcRH1 protein levels by inhibiting BET bromodomains, which would reduce the transcriptional elongation of genes involved in B cell development, including FCRL1. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide might downregulate FcRH1 expression by inhibiting the production of pro-inflammatory cytokines, which could be necessary for the optimal expression of FCRL1 in B cells. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide could hypothetically inhibit FcRH1 expression by enhancing the degradation of transcription factors that drive FCRL1 gene transcription in B-cells. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea might reduce FcRH1 expression by inhibiting ribonucleotide reductase, thus limiting DNA synthesis and potentially decreasing B cell proliferation and FCRL1 gene expression. | ||||||